Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study - PubMed
4 hours ago
- #squamous NSCLC
- #immunotherapy
- #first-line treatment
- Ivonescimab plus chemotherapy significantly extended median progression-free survival (11.1 months) compared to tislelizumab plus chemotherapy (6.9 months) in advanced squamous non-small cell lung cancer patients.
- Treatment-related side effects were common in both groups (99% vs. 98%), with severe side effects more frequent in the ivonescimab group (64% vs. 54%) but serious side effects less frequent (32% vs. 54%).
- Ivonescimab plus chemotherapy reduced the risk of cancer progression by 40% compared to tislelizumab plus chemotherapy, with manageable side effects that minimally impacted quality of life.